A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Ribiciclib|DRUG: Palbociclib|DRUG: Abemaciclib
Sponsor: Novartis Pharmaceuticals